Bacterial Diseases of Goat and Its Preventive Measures

Bacterial diseases of goats can cause huge economical loss to the farmers. Due to intensification of goat farming and poor hygienic practices there is increase in the number of bacterial diseases that affect the goats. Diseases like tuberculosis, Johne’s disease and Brucellosis are chronic diseases that may be identified in the initial stages of infection during which they spread to other animals. Similarly, brucellosis, tuberculosis and also anthrax are zoonotic diseases hence due consideration has to be provided while handling animals suspected for these diseases. Use of vaccine before onset of the disease in endemic areas can prevent the disease outbreak and spread to other naïve population. Good hygienic practices and biosecurity measures at farm are essential to prevent disease spread. The present chapter deals with various bacterial diseases affecting goats and its preventive measures. This chapter can be a guide to field veterinarians, students and farmers as it highlights the important bacterial diseases of goats

Zika Virus- Emergence, Evolution, Pathology, Diagnosis, and Control: Current Global Scenario and Future Perspectives- A Comprehensive Review

This review converses the Zika virus which has attained global concern due to its rapid pandemic potential and impact on humans. Though Zika virus was first isolated in 1947, till the recent large-scale outbreak which occurred in Micronesia, in 2007, the virus was placed into the innocuous pathogen category. The World Health Organization on 1 February 2016 declared it as a Public Health Emergency of International Concern.\u27 Of the note, American as well as Pacific Island strains/isolates is relatively closer to Asian lineage strains. The African and American strains share more than 87.5% and 95% homologies with Asian strains/isolates, respectively. Asian strains form independent clusters, except those isolated from China, suggesting relatively more diversity than African strains. Prevention and control are mainly aimed at the vector population (mosquitoes) with Aedes aegypti being the main species. Surveys in Africa and Asia indicated seropositivity in various animal species. However, so far its natural reservoir is unknown. There is an urgent need to understand why Zika virus has shifted from being a virus that caused mild illness to unforeseen birth defects as well as autoimmune-neurological problems. Unfortunately, an effective vaccine is not available yet. Availability of cryo-electron microscopy based on 3.8 angstrom resolution revealing mature Zika virus structure and the probable virus attachment site to host cell would provide critical insights into the development of antiviral treatments and vaccines

Brzo i vidljivo petljom posredovano izotermno umnažanje za dokazivanje Brucella spp. i njegova primjena u epidemiologiji bruceloze goveda.

Brucellosis is a devastating disease, once an abortion storm starts in a herd, and hence early diagnosis is important. Loop mediated isothermal amplification (LAMP) has enlightened the darker part of the diagnostic world by its simplicity and swiftness, and has the advantage of working in isothermal conditions so that it can be applied to the field. LAMP for Brucella spp., that already exists has not been exploited for visual detection and the time needed for completion of the reaction has not been reduced. In the present study, an attempt was made to seal these cracks by developing a fast and visually detectable LAMP for Brucella spp., which needs only 30 min detection time, and SYBR green aided easier result visualization. The LAMP test targeting the omp25 gene was found to be highly sensitive and specific for detecting Brucella spp. Comparison of the LAMP test with the available PCR assay revealed that the LAMP test was more sensitive than PCR, following testing of 438 field samples of cattle origin, and it showed prevalence of Brucella of 14.7 % in different parts of India. Being highly sensitive, specific and speedy, the standardized visual LAMP test can be widely used for epidemiological surveys of this economically important and zoonotic pathogen.Bruceloza je razorna bolest kad se u stadu pojavi u obliku pobačaja što iziskuje brzo postavljanje dijagnoze. Upotreba metode nazvane „petljom posredovano izotermno umnažanje“ (engl. loop mediated isothermal amplification, LAMP)“ omogućila je poboljšanje dijagnostike svojom jednostavnošću i brzinom, a prednost joj je da se može izvesti na postojanoj temperaturi pa se može primijeniti u terenskim uvjetima. U dosada razvijenim postupcima LAMP-a nije bio rabljen vizualni dokaz i nije se uspjelo skratiti vrijeme reakcije. U ovom istraživanju pokušalo se ukloniti te nedostatke razvitkom brzog postupka za vizualni dokaz Brucella spp., za što je potrebno samo 30 minuta i SYBR zeleno. LAMP test za dokaz gena omp25 pokazao se visoko osjetljivim i specifičnim za dokaz Brucella spp. Pretraga 438 terenskih uzoraka podrijetlom od goveda pokazala je da je LAMP osjetljiviji od raspoloživih testova PCR-a. Tim je testom dokazana prevalencija bruceloze od 14,7 % u različitim dijelovima Indije. Kao vrlo osjetljiv, specifičan i brz, LAMP test se može naširoko upotrijebiti u epidemiološkim istraživanjima bruceloze

Ebola virus - Epidemiology, Diagnosis, and Control: Threat to Humans, Lessons Learnt, and Preparedness Plans - an Update on Its 40 Year\u27s Journey

Ebola virus (EBOV) is an extremely contagious pathogen and causes lethal hemorrhagic fever disease in man and animals. The recently occurred Ebola virus disease (EVD) outbreaks in the West African countries have categorized it as an international health concern. For the virus maintenance and transmission, the non-human primates and reservoir hosts like fruit bats have played a vital role. For curbing the disease timely, we need effective therapeutics/prophylactics, however, in the absence of any approved vaccine, timely diagnosis and monitoring of EBOV remains of utmost importance. The technologically advanced vaccines like a viral-vectored vaccine, DNA vaccine and virus-like particles are underway for testing against EBOV. In the absence of any effective control measure, the adaptation of high standards of biosecurity measures, strict sanitary and hygienic practices, strengthening of surveillance and monitoring systems, imposing appropriate quarantine checks and vigilance on trade, transport, and movement of visitors from EVD endemic countries remains the answer of choice for tackling the EBOV spread. Herein, we converse with the current scenario of EBOV giving due emphasis on animal and veterinary perspectives along with advances in diagnosis and control strategies to be adopted, lessons learned from the recent outbreaks and the global preparedness plans. To retrieve the evolutionary information, we have analyzed a total of 56 genome sequences of various EBOV species submitted between 1976 and 2016 in public databases

Advances in Developing Therapies to Combat Zika Virus: Current Knowledge and Future Perspectives

Zika virus (ZIKV) remained largely quiescent for nearly six decades after its first appearance in 1947. ZIKV reappeared after 2007, resulting in a declaration of an international “public health emergency” in 2016 by the World Health Organization (WHO). Until this time, ZIKV was considered to induce only mild illness, but it has now been established as the cause of severe clinical manifestations, including fetal anomalies, neurological problems, and autoimmune disorders. Infection during pregnancy can cause congenital brain abnormalities, including microcephaly and neurological degeneration, and in other cases, Guillain-Barré syndrome, making infections with ZIKV a substantial public health concern. Genomic and molecular investigations are underway to investigate ZIKV pathology and its recent enhanced pathogenicity, as well as to design safe and potent vaccines, drugs, and therapeutics. This review describes progress in the design and development of various anti-ZIKV therapeutics, including drugs targeting virus entry into cells and the helicase protein, nucleosides, inhibitors of NS3 protein, small molecules, methyltransferase inhibitors, interferons, repurposed drugs, drugs designed with the aid of computers, neutralizing antibodies, convalescent serum, antibodies that limit antibody-dependent enhancement, and herbal medicines. Additionally, covalent inhibitors of viral protein expression and anti-Toll-like receptor molecules are discussed. To counter ZIKV-associated disease, we need to make rapid progress in developing novel therapies that work effectually to inhibit ZIKV

Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus

Human papillomavirus (HPV) is a viral infection with skin-to-skin based transmission mode. HPV annually caused over 500,000 cancer cases including cervical, anogenital and oropharyngeal cancer among others. HPV vaccination has become a public-health concern, worldwide, to prevent the cases of HPV infections including precancerous lesions, cervical cancers, and genital warts especially in adolescent female and male population by launching national programs with international alliances. Currently, available prophylactic and therapeutic vaccines are expensive to be used in developing countries for vaccination programs. The recent progress in immunotherapy, biotechnology, recombinant DNA technology and molecular biology along with alternative and complementary medicinal systems have paved novel ways and valuable opportunities to design and develop effective prophylactic and therapeutic vaccines, drugs and treatment approach to counter HPV effectively. Exploration and more researches on such advances could result in the gradual reduction in the incidences of HPV cases across the world. The present review presents a current global scenario and futuristic prospects of the advanced prophylactic and therapeutic approaches against HPV along with recent patents coverage of the progress and advances in drugs, vaccines and therapeutic regimens to effectively combat HPV infections and its cancerous conditions

A Comprehensive Review on Equine Influenza Virus:Etiology, Epidemiology, Pathobiology, Advances in Developing Diagnostics, Vaccines, and Control Strategies

Among all the emerging and re-emerging animal diseases, influenza group is the prototype member associated with severe respiratory infections in wide host species. Wherein, Equine influenza (EI) is the main cause of respiratory illness in equines across globe and is caused by equine influenza A virus (EIV-A) which has impacted the equine industry internationally due to high morbidity and marginal morality. The virus transmits easily by direct contact and inhalation making its spread global and leaving only limited areas untouched. Hitherto reports confirm that this virus crosses the species barriers and found to affect canines and few other animal species (cat and camel). EIV is continuously evolving with changes at the amino acid level wreaking the control program a tedious task. Until now, no natural EI origin infections have been reported explicitly in humans. Recent advances in the diagnostics have led to efficient surveillance and rapid detection of EIV infections at the onset of outbreaks. Incessant surveillance programs will aid in opting a better control strategy for this virus by updating the circulating vaccine strains. Recurrent vaccination failures against this virus due to antigenic drift and shift have been disappointing, however better understanding of the virus pathogenesis would make it easier to design effective vaccines predominantly targeting the conserved epitopes (HA glycoprotein). Additionally, the cold adapted and canarypox vectored vaccines are proving effective in ceasing the severity of disease. Furthermore, better understanding of its genetics and molecular biology will help in estimating the rate of evolution and occurrence of pandemics in future. Here, we highlight the advances occurred in understanding the etiology, epidemiology and pathobiology of EIV and a special focus is on designing and developing effective diagnostics, vaccines and control strategies for mitigating the emerging menace by EIV

DNA vaccine: the miniature miracle

DNA, the essential part of the life is making way in to new vaccine technology. Plasmid vectors from the bacteria have revolutionized the world of vaccine design by its new technology – DNA vaccines. Small portion of the nucleotides from the pathogen held under the control of promoter in a plasmid vector can be used as a vaccine. DNA vaccines alleviate the odds of the other vaccines by having good hold on both the faces of the immunity. The key to the success of DNA vaccine lies in the route of administration of the vaccine which can be done in many ways. Prime boost strategy is an approach used to boost the action of DNA vaccine. To date there are only four DNA vaccine available in the market. [Vet World 2013; 6(4.000): 228-232

Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19

Coronavirus disease-2019 (COVID-19) pandemic has become a global threat and death tolls are increasing worldwide. The SARS-CoV-2 though shares similarities with SARS-CoV and MERS-CoV, immunopathology of the novel virus is not understood properly. Previous reports from SARS and MERS-CoV documents that preexisting, non-neutralizing or poorly neutralizing antibodies developed as a result of vaccine or infection enhance subsequent infection, a phenomenon called as antibody-dependent enhancement (ADE). Since immunotherapy has been implicated for COVID-19 treatment and vaccine is under development, due consideration has to be provided on ADE to prevent untoward reactions. ADE mitigation strategies like the development of vaccine or immunotherapeutics targeting receptor binding motif can be designed to minimize ADE of SARS-CoV-2 since full-length protein-based approach can lead to ADE as reported in MERS-CoV. The present mini-review aims to address the phenomenon of ADE of SARS-CoV-2 through the lessons learned from SARS-CoV and MERS-CoV and ways to mitigate them so as to develop better vaccines and immunotherapeutics against SARS-CoV-2